NCT06561685 2026-02-10A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsEli Lilly and CompanyPhase 1 Recruiting340 enrolled
NCT04704934 2026-01-12Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Daiichi SankyoPhase 3 Active not recruiting490 enrolled